Sientra (NASDAQ:SIEN) had its target price cut by investment analysts at Canaccord Genuity from $19.00 to $18.00 in a research report issued to clients and investors on Wednesday, March 14th. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Canaccord Genuity’s price objective would suggest a potential upside of 94.38% from the stock’s previous close.
Other equities analysts have also issued research reports about the company. ValuEngine raised Sientra from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. BidaskClub upgraded Sientra from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Stifel Nicolaus upgraded Sientra from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Friday, January 19th. Finally, Lake Street Capital downgraded Sientra from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $11.00 in a report on Wednesday, February 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Sientra has a consensus rating of “Hold” and an average target price of $13.50.
Shares of Sientra stock traded down $0.09 on Wednesday, hitting $9.26. The stock had a trading volume of 157,654 shares, compared to its average volume of 214,195. Sientra has a one year low of $7.20 and a one year high of $16.68. The stock has a market capitalization of $181.90, a price-to-earnings ratio of -3.28 and a beta of -1.06.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, March 13th. The medical instruments supplier reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). The business had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $11.90 million. Sientra had a negative return on equity of 107.35% and a negative net margin of 175.22%. The business’s revenue was up 70.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.43) EPS. analysts forecast that Sientra will post -2.68 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of the company. Vident Investment Advisory LLC purchased a new position in shares of Sientra during the 4th quarter valued at about $481,000. Two Sigma Investments LP lifted its holdings in Sientra by 120.1% in the 4th quarter. Two Sigma Investments LP now owns 32,382 shares of the medical instruments supplier’s stock worth $455,000 after purchasing an additional 17,668 shares in the last quarter. Two Sigma Advisers LP purchased a new position in Sientra in the 4th quarter worth approximately $391,000. Deutsche Bank AG lifted its holdings in Sientra by 24.9% in the 4th quarter. Deutsche Bank AG now owns 33,499 shares of the medical instruments supplier’s stock worth $470,000 after purchasing an additional 6,669 shares in the last quarter. Finally, Senzar Asset Management LLC raised its holdings in shares of Sientra by 271.6% during the 4th quarter. Senzar Asset Management LLC now owns 484,607 shares of the medical instruments supplier’s stock worth $6,814,000 after acquiring an additional 354,200 shares in the last quarter. 77.38% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/canaccord-genuity-cuts-sientra-sien-price-target-to-18-00.html.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.